DOI : 10.1055/s-00034924

Nuklearmedizin - NuclearMedicine

Issue 02 · Volume 60 · April 2021 DOI: 10.1055/s-011-50684

Deutsche Gesellschaft für Nuklearmedizin
NuklearMedizin 2021 – digital
, 14.-17.04.2021

Prof. Dr. Michael Schäfers
Abstracts (HTML) Abstracts (PDF) List of Authors
P18
Alberts, I; Seide, SE; Mingels, C; Bohn, KP; Shi, K; Zacho, HD; Rominger, A; Afshar-Oromieh, A: The diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis
P19
Alberts, I; Sachpekidis, C; Prenosil, GA; Viscione, M; Bohn, KP; Mingels, C; Shi, K; Afshar-Oromieh, A; Rominger, A: Digital PET/CT allows for shorter acquisition protocols or reduced radiopharmaceutical dose in [18F]-FDG PET/CT
P20
Miksch, J; Strauß, AS; DiCarlo, D; Bolenz, C; Wiegel, T; Solbach, C; Prasad, V; Wester, HJ; Eiber, M; Beer, AJ: [F-18]siPSMA14 zeigt 90min p.i. ohne forcierte Diurese eine hohe Untersucherübereinstimmung in Primär- und Re-Staging von Prostatakarzinom Patienten
P21
Alberts, I; Hünermund, JN; Sachpekidis, C; Mingels, C; Fech, V; Bohn, KP; Rominger, A; Afshar-Oromieh, A: The influence of digital PET/CT on diagnostic certainty and interrater reliability in 68Ga-PSMA-11 PET/CT for recurrent prostate cancer
P22
Winkens, T; Rudakoff, W; Rauchfuss, F; Freesmeyer, M: Incidental findings on FDG-PET/CT in HCC patients – relevant information for patients considered for liver transplantation?
P23
Mingels, C; Hünermund, J; Bohn, KP; Rominger, A; Afshar-Oromieh, A; Alberts, I: Diagnostic performance of F-18-PSMA-1007 PET/CT in hormone naïve patients with first biochemical recurrent prostate cancer post radical prostatectomy
P24
Mittlmeier, LM; Beyer, L; Todica, A; Herlemann, A; Kretschmer, A; Schmidt-Hegemann, NS; Kunz, WG; Ricke, J; Bartenstein, P; Ilhan, H; Unterrainer, M: Feasibility of different tumor delineation approaches for 18F-PSMA-1007 PET/CT imaging in patients with metastatic prostate cancer
P25
Buchholz, HG; Rosar, F; Betz, A; Miederer, M; Ezziddin, S; Schreckenberger, M: Nierenfunktionsbestimmungen mittels Ga-68-PSMA-PET/CT
P26
Brose, A; Nestle, U; Michalski, K; Tosch, M; König, J; Schreckenberger, M; Ruf, J; Miederer, M: Der SULpeak und die Tumor Lesion Glycolysis als Prognoseparameter in der FDG-PET/CT beim lokal fortgeschrittenen Lungenkarzinom
P27
Weber, M; Rauscher, I; Gafita, A; Herrmann, K; Wetter, A; Ferdinandus, J; Seifert, R; Rahbar, K; Hadaschik, B; Eiber, M; Fendler, WP: PSMA-PET for metastatic hormone-sensitive prostate cancer: A multicenter trial
P28
Weissinger, M; Atmanspacher, M; Dittmann, H; Gatidis, S; Zender, L; la Fougère, C: Dynamische Ganzkörper 18F-FDG-PET/CT bei Patienten mit unklaren Lungenrundherden
P29
Alberts, I; Hünermund, JN; Sachpekidis, C; Zacho, HD; Mingels, C; Bohn, KP; Läppchen, T; Gourni, E; Rominger, A; Afshar-Oromieh, A: Combination of forced diuresis with additional late imaging in 68Ga-PSMA-11PET/CT – an optimised imaging protocol
P30
Mingels, C; Sachpekidis, C; Bohn, KP; Hünermund, J; Schepers, R; Fech, V; Prenosil, GA; Rominger, A; Afshar-Oromieh, A; Alberts, I: The influence of colour scale in lesion detection and patient based sensitivity in Ga-68-PSMA-PET/CT